MASS
$6.11+0.02 (+0.33%)
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices for use in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices for use in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. Its products i...
Recent News
908 Devices Calls “Inflection Point,” Targets 15%-20% 2026 Growth on Field Detection Demand
Executives from 908 Devices (NASDAQ:MASS) outlined what they described as an “inflection point” for the company, emphasizing its focus on bringing lab-grade chemical analysis technologies into field-ready handheld and portable devices for public health, safety, and defense use cases. Field-based ch
908 Devices Inc. Q4 2025 Earnings Call Summary
Moby summary of 908 Devices Inc.'s Q4 2025 earnings call
908 Devices Inc (MASS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
908 Devices Inc (MASS) reports significant revenue growth and strategic moves to enhance operational efficiency and future growth potential.
908 Devices Q4 Earnings Call Highlights
908 Devices (NASDAQ:MASS) reported fourth-quarter and full-year 2025 results that management said reflected continued momentum from its strategic transformation, including stronger adoption of its handheld chemical analysis devices and improved profitability metrics. Fourth-quarter growth driven by
908 Devices (MASS) Q4 2025 Earnings Transcript
Kevin J. Knopp: Good morning, and thank you for joining our fourth quarter and full year 2025 earnings call. This performance was driven primarily by three factors: one, continued demand for our Explorer gas identification device by firefighters and hazmat response teams; two, strong initial demand for Viper, our new product that provides simple and fast chemical analysis of solids and liquids; and three, continued strong adoption of all of our products by U.S. state and local customers. Most importantly, we achieved positive adjusted EBITDA in the fourth quarter of $700,000, which is a remarkable improvement from the prior year's loss of $4 million.